MicroRNA-seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data

Biomarker Insights

Volumn 10, Issue , 2015, Pages 21-31

  Satoh, Jun Ichi ^a   Kino, Yoshihiro ^a   Niida, Shumpei ^b  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer s disease; Biomarkers; Data analysis pipeline; DIANA miRPath; MicroRNA; OmiRas; Small RNA Seq

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 103A 3P; MICRORNA 1294; MICRORNA 144 5P; MICRORNA 1468; MICRORNA 148A 3P; MICRORNA 148B 5P; MICRORNA 151A 3P; MICRORNA 15A 5P; MICRORNA 17 3P; MICRORNA 186 5P; MICRORNA 26A 5P; MICRORNA 26B 3P; MICRORNA 28 3P; MICRORNA 29B 3P; MICRORNA 30C 5P; MICRORNA 30D 5P; MICRORNA 3200 3P; MICRORNA 425 5P; MICRORNA 4781 3P; MICRORNA 5001 3P; MICRORNA 5010 3P; MICRORNA 502 3P; MICRORNA 532 5P; MICRORNA 550A 5P; MICRORNA 6513 3P; MICRORNA 660 5P; MICRORNA 98 5P; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL COMMUNICATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; RNA SEQUENCE; SEQUENCE ANALYSIS; SYNAPTOSOME; UPREGULATION;

EID: 84930661401     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S25132     Document Type: Article

References (34)

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological altera­tions in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
2. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168–74.
3. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer’s dis­ease. Ther Adv Neurol Disord. 2011;4(4):203–16.
4. Geldmacher DS, Whitehouse PJ Jr. Differential diagnosis of Alzheimer’s dis­ease. Neurology. 1997;48(5 suppl 6):S2–9.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
6. Antila K, Lötjönen J, Thurfjell L, et al. The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer’s disease. Interface Focus. 2013;3(2):20120072.
7. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predom­inantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–40.
8. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63.
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.
10. Keller A, Leidinger P, Bauer A, et al. Toward the blood-borne miRNome of human diseases. Nat Methods. 2011;8(10):841–3.
11. Satoh J. Molecular network analysis of human microRNA targetome: from can­cers to Alzheimer’s disease. BioData Min. 2012;5(1):17.
12. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.
13. Satoh J. Molecular network of microRNA targets in Alzheimer’s disease brains. Exp Neurol. 2012;235(2):436–46.
14. Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer’s disease in biological fluids using next-generation sequencing technologies. Front Genet. 2013;4:150.
15. Vallelunga A, Ragusa M, Di Mauro S, et al. Identification of circulating microR­NAs for the differential diagnosis of Parkinson’s disease and multiple system atrophy. Front Cell Neurosci. 2014;8:156.
16. Fineberg SK, Kosik KS, Davidson BL. MicroRNAs potentiate neural develop­ment. Neuron. 2009;64(3):303–9.
17. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportuni­ties. Nat Rev Genet. 2011;12(2):87–98.
18. Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14(7):R78.
19. Müller S, Rycak L, Winter P, Kahl G, Koch I, Rotter B. omiRas: a Web server for differential expression analysis of miRNAs derived from small RNA-Seq data. Bioinformatics. 2013;29(20):2651–2.
20. Vlachos IS, Kostoulas N, Vergoulis T, et al. DIANA miRPath v.2.0: investi­gating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40(Web Server issue):W498–504.
21. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.
22. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integra­tion and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40(Database issue):D109–14.
23. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analy­sis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
24. Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17):6415–20.
25. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012;235(2):491–6.
26. Hu CW, Tseng CW, Chien CW, et al. Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. J Proteome Res. 2013;12(9):3993–4004.
27. Lau P, Bossers K, Janky R, et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med. 2013;5(10):1613–34.
28. Müller S. In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in Huntington’s disease. Transl Neurodegener. 2014;3:17.
29. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY). 2013;5(12):925–38.
30. Bhatnagar S, Chertkow H, Schipper HM, et al. Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Front Mol Neurosci. 2014;7:2.
31. Kumar P, Dezso Z, MacKenzie C, et al. Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One. 2013;8(7):e69807.
32. Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry. 2014.
33. Tan L, Yu JT, Tan MS, et al. Genome-wide serum microRNA expression pro­filing identifies serum biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2014;40(4):1017–27.
34. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregu­lated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645–59.